The Spanner Insertion and Removal

Dr. Neal Shore will guide urologists through the techniques necessary to insert and remove a temporary prostatic stent in their clinical practice.

To read a physician-authored article in Urology Times detailing the use of the Spanner prostatic stent, please click here.

Additional References and Resources
Shore ND, Dineen MK, Saslawsky MJ. A Temporary Intraurethral Prostatic Stent Relieves Prostatic Obstruction Following Transurethral Microwave Thermotherapy. J Urol. 2007; 177(3):1040-1046.

Dineen MK, Shore ND, Lumerman JH. Use of a temporary prostatic stent after transurethral microwave thermotherapy reduced voiding symptoms and bother without exacerbating irritative symptoms . Urology. 2008 May;71(5):873-7. Epub 2008 Mar 28.

Bladder Cancer: Get the Facts – Urology Care Foundation

Urology

Bladder cancer is the 10th most common cancer globally. It details the risk factors, such as aging, smoking, and exposure to certain chemicals, and emphasizes the importance of early detection....

► 5:47

Immune TME Heterogeneity Revealed Via scRNA-seq

In an interview conducted during the 2021 Genitourinary Cancers Symposium, Peter Reisz, MD, a urologic oncology fellow at Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the use of single-cell...

► 10:04

Long-Term Follow-Up of POUT

Oncology

In an interview conducted during the 2021 Genitourinary Cancers Symposium, Alison Birtle, MD, consultant clinical oncologist and honorary clinical senior lecturer at Lancashire Teaching Hospitals, Preston, UK, discusses updated results...

► 3:54

Immune Checkpoint Inhibitors in Upper and Lower Tract Urothelial Carcinoma

Oncology

In an interview conducted during the 2021 Genitourinary Cancers Symposium, Petros Grivas, MD, PhD, a physician at Seattle Cancer Care Alliance, associate professor at Fred Hutchinson Cancer Research Center, and...

The Urology Channel

The Spanner Insertion and Removal

More in Urology

Bladder Cancer: Get the Facts – Urology Care Foundation

Urology

Immune TME Heterogeneity Revealed Via scRNA-seq

Oncology

Long-Term Follow-Up of POUT

Oncology

Immune Checkpoint Inhibitors in Upper and Lower Tract Urothelial Carcinoma

Oncology